Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases.
Metastatic renal cell carcinoma (mRCC) is a difficult to treat malignancy and currently Sunitinib is a standard of care first-line therapy. A new metastasis during the treatment is considered a sign of drug failure and alternative therapeutic methods should be tried. Here, we report 2 cases of newly diagnosed isolated metastasis during Sunitinib treatment of mRCC patients. Our management plan included local palliative therapy to the lesion followed by recommencing of Sunitinib. This resulted in a good symptomatic relief locally as well as good overall control of the disease.
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, UK. ashablak @ picr.man.ac.uk
Alaaeldin
A
Shablak
Jackie
J
O'Dwyer
Robert
R
Hawkins
Ruth
R
Board
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008495:Medical Oncology / Q000379:methods; D009362:Neoplasm Metastasis; D010166:Palliative Care / Q000379:methods; D011758:Pyrroles / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D011838:Radiation-Sensitizing Agents; D042461:Vascular Endothelial Growth Factor A; D000077210:Sunitinib